Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival; however, relapses are common. A number of receptor tyrosine kinases (RTKs) including EGFR and MET have been reported to be involved in CMM metastasis and in the development of resistance to therapy, ta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Das, Ishani, Wilhelm, Margareta, Höiom, Veronica, Franco Marquez, Rodolfo, Costa Svedman, Fernanda, Hansson, Johan, Tuominen, Rainer, Egyhàzi Brage, Suzanne
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737096/
https://ncbi.nlm.nih.gov/pubmed/31506424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-019-1875-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados